the global cannabis€¦ · 14-01-2019 · distinguished resume includes director for mars...

MEDICAL

MEDICAL & RECREATIONAL

The Global Cannabis

Landscape.“The global legal marijuana

market is expected to reach

USD 146.4 Billion by end of

2025” — Grand View Research, Inc.

April 2018

3 TSX.V:PURE OTC:PRCNF FRA:1QS

Comprised of industry experts, our team is dedicated to

producing the highest quality – consistently pure – cannabis

products. Our vision is to harness the therapeutic

properties of cannabis in tomorrow’s medicines and

consumer products to become the world’s most trusted

brand.

Canadian Leadership With A Pure Global View


Management

Michael Lavergne

Head of Supply Chain

Hands-on sustainable supply

chain and operations

professional with 20 years of

multinational experience in fast-

moving consumer goods

(FMCG) / retail. Former VP

Global Supply Chain Shoppers

Drug Mart, held senior positions

at Joe Fresh and Walmart.

Nader Gheshlaghi, PhD, MSc

VP, Production, PureSinse Inc.

World renowned Plant

Genetics & Pathologist, has

managed large-scale grow

operations for hundreds of

medical and commercial plant

varieties around the world with

international industry and

academic awards, and many

patents.

Trupti P. Smit, LLBDirector of Corporate and

Legal Affairs

15 years as cross border

transactions, corporate,

intellectual property, commercial

and international tax lawyer;

Legal Counsel at RBC

International Tax and Transfer

Pricing.

Malay Panchal, RPh, BScPhm

Founder & CEO, Board Member

A seasoned serial-entrepreneur

with 20+ years experience in

pharma B2B technology, retail

and mail-order pharmacy,

pharma branding and clinical

trials.

Stephen Pynn

VP, Corporate Development

Significant experience in Capital

Markets and Corporate Finance

with a focus primarily on the

cannabis sector’s financings and

public offerings. Former cannabis

Capital Markets expert at PI

Financial Corp. participated in

over $800M of financings.

Vishwas Sawant, MBA

General Manager, PureSinse

30 years of global experience in

heavy engineering manufacturing,

agribusiness, retail and IT.

Former CEO, Farmers Co-op,

India, 55M CAD revenue, 1200

employees.

Bhup Gosain, CPA, CA, CPA

(IL)

Chief Financial Officer

30+ years experience in tax and

business advisory services in a

variety of sectors including

technology, life sciences,

biotechnology, natural resources

and pharma. Former senior

management at Deloitte and partner

at MNP.


Ross Hendry

VP, Marketing

A seasoned veteran of the Alcohol

Beverage industry with over 15

years experience and holding

leadership positions across

Commercial and Marketing

functions. Working in some of

the industry's most recognizable

companies, such as AB InBev

and Pernod-Ric.

Sandra Couto, RPh, BSc Pharm

Clinical Affairs and Partnerships

A trained pharmacist and leader in

the Canadian pharmaceutical

sector for more than 20yrs, with

expertise in medical affairs, clinical

development and product training,

Sandra will drive the scientific

objectives of PureSinse. Former

Director of Clinical Partnership and

Stakeholder Relations, at University

Health Network.

Sanjeev Goel, MD

Chief Medical Officer

Dr. Goel is a multi-disciplinary

physician trained in traditional,

holistic, anti-aging, integrative

and regenerative medicine. Prior

to joining PureSinse he

developed the largest patient

portal in Canada. He has

extensive experience prescribing

cannabis and has operated

several cannabis clinics.

Board

Dr. Chandra Panchal, PhD

Chairman

Distinguished resume includes

Director for MaRS Innovation, senior

scientist at John Labatt Ltd., and

Chairman, President and CEO at

Procyon Biopharma Inc. CEO of

Axelon pharma, Director in several

public companies.

Jane Pagel, MSc

Board Member

Retired executive with extensive

experience, previously held

positions as the President & CEO

of the Ontario Clean Water

Agency, and Director of Research

& Technology at the Ministry of the

Environment.

Brian O’Neill, BSc, LLB

Board Member

Nearly a decade in the practice of

law at a leading national law firm,

focused on M&A, corporate

reorganizations, corporate finance,

intellectual property, and

commercial transactions. BSc

(Hon) Molecular Genetics, 10 years

at McCarthy Tetrault LLP.

Albert Beraldo, CPA, CA

Board Member

More than 30 years’ experience in

various senior leadership roles within

the pharmaceutical and biotechnology

industry, including Founder & CEO of

Alveda Pharmaceuticals Inc.


Trina Fraser

Brazeau Seller Law

The foremost cannabis policy and

regulatory expert in the industry,

Trina is actively working with Pure

Global on regulatory affairs and

licensing applications.

Jim Youmans

Rx Samples Solutions USA

40+ years experience in corporate

pharma. Former CMO Glaxo global,

Former President Sandoz Global,

Former COO Novartis Global advising

on medical branding, sales and

market strategies.

Paul SparkesNorris Point Capital

Former senior aid to two Premiers,

Director of Operations to Prime

Minister Chretien, former LCBO

board member; advising on market

penetration strategies.

Industry Advisors

Dr. Matthew D. Burnstein BSc, MD

Appletree Medical Group

Over 35 years of practice as a family

physician. Certified Medical Review

Officer, trained to develop workplace drug

and alcohol programs, as well as

interpret drug tests.

Pure Capital Structure

TSX.V:PURE

OTC:PRCNF

FRA:1QS

$0.35/share*

Market cap $52M

Issued and outstanding 148.2M

Warrants and options 48.8M

Fully diluted 197M

Cash $14.7M

Debt $0

Convertible debentures shares reserved for issuance 10M

Management and Insider Ownership 21%*As at September 30, 2018


Market Cap Range: $34M - $21B

Average Market Cap - $1.35B

Median Market Cap - $190M

➢ Pure Global Cannabis (TSX.V:PURE)

$52M market cap

➢ Sales License Achieved Jan 11/19

➢ Purification, Packaging, Processing and

Extraction Capabilities

➢ Clinical Partnerships

➢ E-Commerce Platform

Canadian Public LP Universe

Source: Company Reports, Thomson Eikon, SEDAR, Analyst Estimates, Basic Market Capitalization as of January 9, 2019


Why Own Pure Global?Solid Foundation and Exciting Pipeline

Medicinal, Consumer &

Pharma Focus

Exceptional Leadership

Team & Disruptive

Intellectual Property

Why Pure Global is the next generation Cannabis 3.0

Purification/Extraction

Capabilities and Sales

Licensing Achieved

Medical Research study initiated

with Appletree and a leading global

Clinical Research Organization –

large scale peer-reviewed study

which will be the first of its kind

PURE received its Sales License

on January 11th, 2019

Focused on domestic &

international distribution - medical

clinics, consumer and wellness

segment, EU & Latin American

exports

Canada’s first multi-ponic cannabis

farm, a patent pending system

producing yields several fold greater

than traditional operations

Patent-pending high-efficiency

vertical farm method maximizes

utility of production footprint

Seasoned horticulture expert who is

a world-renowned specialist in plant

genetics, commercial scale indoor,

greenhouse manufacturing

Adapting pharmaceutical

technologies to develop unique

cannabis formulations for specific use

cases

IP driven for production/extraction

capabilities, strain development, and

unique pharma and consumer

products

PureSinse™ is a medical and

pharma focused brand

Market segment targeted

consumer brands to launch H1

2019

Strategic partnership with:

Appletree Medical Group Inc.

• 35 locations – 700,000

patients. One of the largest

community medical groups

in Canada

Spark Medical Clinics

• Clinical team of physicians,

nurses and pharmacists

who support cannabis

patients across the GTA

GMP grade product offerings for

International/EU distribution


Purification, packaging, and

processing readiness for high

capacity production of capsules, oil

vials, tinctures, and vape pens

Super critical CO2 oil extraction

facility under construction

Principal focus on post-derivative

manufacturing, purification and

extraction

Innovation through R&D and ongoing

clinical studies to drive targeted

medical, consumer, and pharma

product development

Co-Packaging agreements and

product distribution via strategic

clinical partnerships across Canada

Clinical Cannabinoid Education

Network (CCEN) a non-profit

educational and networking platform

for the medical community

Pharma product pipeline and

research backed education for the

medical community

➢ PureSinseTM

– Medical focused brand, wholly owned

subsidiary, PureSinse Inc, licensed to cultivate under the

Cannabis Act, received its Sales License on January 11th,

2019

➢ Completed Phase 1 Buildout – Extraction, QA &

Microbiology Labs including Order Processing & Packaging,

Shipping & Receiving. Phase 1 ready

➢ Fully-secured Inventory - Secured inventory in excess of

$3M with agreements with a number of top tier Licensed

Producers, pursuing additional long-term supply agreements

➢ GMP/ISO Facility + R&D Lab – Initiated data collection for

European Good Manufacturing Practice (”euGMP") and ISO

certifications (euGMP expected H2 2019), along with

investment in advanced analytical R&D laboratory for product

formulation, analytics, derivatives and extracts processing

➢ Revenue Generation & Distribution - Customer acquisition,

branding, and sales strategy includes partnerships with major

Canadian medical clinics, along with the expected inclusion in

future provincial product calls nationwide - revenue generation

to commence the week after sales licensing

Ready for Medical & Consumer Sales

Phase 3 Facility

Expansion

Estimated

H2 2019

Sales License ReceivedJanuary 11,

2019

ACMPR Cultivation

License Received

December

2017

Secured Product InventoryMay-Sept

2018


Phase 2 Facility

Expansion

Estimated

H1 2019

The Root

Is The Heart:Closed-loop systems allow us to

tailor the biochemistry and nutrients

to deliver exactly what the roots need

at every stage for optimal growth.

Best

In Class:Targeted spectrum LED lighting

systems ensure the plant expends

all its energy on growing the purest,

most abundant high-grade flower.

More Canopy, Less Space:Vertical farming enables us to grow

multiple tiers of canopy, exponentially

increasing potential yield from the

same square footage.

Individual

Attention:

Utilizing controlled-growth environments,

every plant is meticulously cared for and

monitored throughout its life cycle to

ensure optimal growth.

Canada’s First Multi-PonicCannabis FarmPure’s VP of Production is an award-winning plant geneticist and horticulture

specialist, with extensive experience growing hundreds of plant varieties and

managing commercial-scale grow operations across the globe.

Pure has designed a unique multi-ponic* growing system that combines the best-

practices of hydroponics, bubbleponics, and aeroponics, with world-class

commercial agriculture methodologies. Our automated system is capable of

growing more plants in less time, without the use of herbicides or pesticides.

*Patent pending

Yield

of similar

footprint3x


PureSinse™-Dedicated to Serving the Medical Community

➢ Medical and Innovation focused branding to patient

and medical community

➢ Partnerships with clinics, health care professionals,

and patient advocacy groups nation-wide

➢ R&D driven - investing in accelerated pharma drug

and product development with JVs with large

pharma, hospitals, and academia

➢ Client Experience and Patient Centricity is at the

top of our list of priorities

➢ Driven by Trust by uncompromising quality and

product consistency by leveraging GMP and ISO

standards


™

Carefully Curated Wellbeing


True to its name, this strain has a

pungent, earthy profile. Some patients

report Diesel helps combat lack of

appetite, nausea, stress and pain. Given

its moderate amount of THC, new

patients are advised to begin by using

gently at night. Diesel is a 60% Sativa

Dominant Hybrid.

Diesel Flower

THC 14.80% | CBD 0.07%

Mildly earthy and sweet flavour notes.

Reported to help alleviate pain, insomnia,

stress and depression. With its high THC

content, we only recommend this strain

for experienced cannabis patients.

Sensi Star Flower

THC 19.22% | CBD 0.00%

Lush in tropical trichome aromas and an

earthy palate. Reported to help manage

stress, pain and depression. Due to its

high THC content, new patients should

start with a low dose and take things

slowly.

Wappa Flower

THC 16.91% | CBD 0.00%

A celebrated Canadian hybrid with a sour

citrus aroma. Some patients find this well-

balanced strain helps them manage

stress, depression, pain and fatigue.

Perfect for morning use by THC-

experienced patients.

Jean Guy Flower

THC 17.36% | CBD 0.00%

Path to Higher Margins with Concentrates

➢ The foundation for most medical, pharma, and consumer

products are cannabis concentrates which result in higher

margins

➢ Equipment installed for oils purification and formulation, with

robotic packaging for high capacity filling of capsules, bottles,

and vape pen cartridges

➢ High capacity super critical CO2 oil extraction capabilities under

construction for Q1 2019 readiness

➢ Entire facility designed to GMP and ISO standards to allow for

international sales and distribution

Seedlings &

Clones

Edibles &

Beverages

Soft Gels &

Capsules

Transdermal

Patch

Cannabis Oils

Sublingual

Strip/Spray

Dried

Flower

TopicalsVape Pen

Cartridges

Wellness

Products


Pharmaceutical

The Medical Opportunity


Medical Condition Canadian Sufferers Est % Use Est # Users

AIDS 71,300 25% 17,825

ADD 399,300 1% 3,993

Alzheimer’s 500,000 1% 5,000

Arthritis 4,376,806 2% 87,536

Asthma 3,000,000 1% 30,000

Cancer 840,000 6% 50,400

Chemotherapy 200,000 10% 20,000

Chronic Pain 6,600,000 3% 198,000

Crohn’s 200,000 2% 4,000

Depression 1,650,000 3% 49,500

Fibromyalgia 343,000 1% 3,430

Epilepsy/seizures 330,000 1% 3,300

Glaucoma 400,000 1% 4,000

Hepatitis C 242,500 1% 2,425

Head Injury 50,000 1% 500

Hypertension 4,600,000 1% 46,000

Migranes 2,000,000 3% 60,000

Multiple Sclerosis 43,890 8% 3,511

Psychological Conditions 6,026,000 1% 60,260

Spinal Cord Injury 86,000 1% 860

Stress 17,250,000 2% 345,000

PURE’s estimated # of Medicinal Cannabis Patients in

Canada995,540

Canadian Sufferers figures Source: Statistics Canada

A Wellness ApproachThe global wellness industry grew 12.8% from 2015-2017,

from a $3.7 trillion to a $4.2 trillion market – Global Wellness Institute, Nov 2018


Key segments include:

➢ Beauty & Anti-Aging ($999 bil.)

➢ Healthy Eating, Nutrition & Weight Loss ($648 bil.)

➢ Wellness Tourism ($563 bil.)

➢ Fitness & Mind-Body ($542 bil.)

➢ Preventative & Personalized Medicine and Public Health ($534 bil.)

➢ Complementary & Alternative Medicine ($199 bil.)

➢ Wellness Lifestyle Real Estate ($119 bil.)

➢ Spa Industry ($99 bil.)

➢ Thermal/Mineral Springs ($51 bil.)

➢ Workplace Wellness ($43 bil.)

Wellness

Products

Topicals

Edibles &

Beverages

Clinic Partnerships, Insurance, Distribution, and Real World Evidence Research Study

13 TSX.V:PURE OTC:PRCNF

Strategic Partnership Appletree Medical Group

➢ Appletree is one of the largest multidisciplinary community medical groups in Canada –

more than 700,000 patients from its 35 medical centers in Ottawa and the Greater Toronto

Area – major channel partner for PureSinse with direct ePrescribing interface

Research Study with Appletree Medical Group

➢ Partnership with Appletree and a leading Clinical Research Organization to launch a large-

scale, peer-reviewed Real-World-Evidence-Based Study on the efficacy of medical

cannabis for the treatment of a range medical conditions. Will guide pharma drug

development.

➢ Clinical Study will examine which cannabis strains and cannabinoid (CBD)-terpene

combinations provide the most therapeutic efficacy for a variety of conditions

Insurance and Distribution

➢ Partnership with Evergreen Pacific Insurance Corp – founding sponsor of the Alternative

Health Association of Canada. Preferred provided status

➢ BuyWell.ca eCommerce marketplace with 10,000+ curated health and wellness products &

services

➢ Distribution to medical community through physician detailing and engagement with several

leading cannabis clinics across Canada


Clinical Cannabinoid Education Network

13 TSX.V:PURE OTC:PRCNF18 TSX.V:PURE OTC:PRCNF FRA:1QS

“As a doctor, what can I

expect from CCEN?”➢ A non-profit pan-Canadian educational

and networking platform for physicians

and Health Care Providers interested

in prescribing cannabis medical

➢ Established by medical leaders for

medical providers who are interested in

sharing knowleged and research

backed evidence about the science of

medical cannabis and its place in

clinical practices

➢ Forum to facilitate optimized care for

medical cannabis patients and provide

research backed education to the

medical community

A Trusted Platform that Delivers:

1. Educational CME events and

conferences

2. Quarterly newsletters

3. Access to podcasts and research

initiatives and educational tools

4. Support and education for medical

cannabis patients

5. Genetic testing and tools to assist with

strain selection and dosing

6. Expedited access to medical cannabis

clinics and service

pureglobal.com | [email protected]

the global cannabis€¦ · 14-01-2019 · distinguished resume includes director for mars...

Documents